UroGen Pharma (URGN) Earnings Date & Reports

Key Takeaways

• UroGen Pharma is scheduled to report second quarter 2026 financial results on Wednesday, August 5, 2026, before the market opens.
• Wall Street consensus estimates point to revenue of approximately $61.6 million and an earnings per share (EPS) loss of roughly $0.30, according to Yahoo Finance data.
• This will be the second full quarter of commercial sales for ZUSDURI, the company's newly launched treatment for low-grade non-muscle invasive bladder cancer (LG-NMIBC).
• In Q1 2026, ZUSDURI posted $29.2 million in revenue with 256 unique prescribers — more than double the prior quarter — setting a high bar for Q2 performance.
• JELMYTO, the company's established therapy for low-grade upper tract urothelial cancer (LG-UTUC), has full-year 2026 revenue guidance of $97 million to $101 million.
• The company ended Q1 2026 with $140.3 million in cash, cash equivalents, and marketable securities, making cash runway a key monitoring point.

Earnings Context and Why It Matters

UroGen Pharma's second quarter 2026 earnings report represents a pivotal checkpoint for the company's commercial transformation. Following the December 2025 U.S. Food and Drug Administration (FDA) approval and subsequent launch of ZUSDURI — a sustained-release mitomycin formulation for LG-NMIBC — the company has shifted from a single-product story centered on JELMYTO to a dual-franchise oncology player. Q1 2026 results revealed explosive early adoption, with ZUSDURI generating $29.2 million in its first partial quarter and prescriber counts more than doubling. Q2 will be the first full quarter to reflect normalized demand trends, conversion cycle improvements, and the community urology channel expansion that management has prioritized. For investors, this report will either validate the bullish thesis of a rapid commercial ramp or raise questions about whether early enthusiasm has peaked.

Earnings Expectations

Analyst consensus for UroGen Pharma's second quarter of 2026 points to meaningful year-over-year improvement driven almost entirely by ZUSDURI's contribution. According to Yahoo Finance, the average revenue estimate among eight analysts sits at $61.59 million, with a low estimate of $56.91 million and a high of $66.50 million. For context, revenue in the year-ago Q2 2025 period was just $24.21 million — implying expected growth of approximately 154%. On the bottom line, consensus EPS stands at -$0.30, a sharp improvement from -$1.05 per share in Q2 2025, reflecting both higher revenue and operating leverage.

Key metrics investors will scrutinize beyond the headline numbers include the number of unique and repeat prescribers for ZUSDURI, the patient enrollment form (PEF)-to-treatment cycle time (which improved from 45–60 days in Q4 2025 to 30–35 days in Q1 2026), and the hospital-to-community practice mix shift. Management has targeted a steady-state cycle time of two to three weeks and a roughly 50/50 split between hospital and community settings — progress on both fronts will signal the durability of the launch trajectory. JELMYTO revenue stability and full-year guidance confirmation will also be closely watched.

AI Screener

For investors looking to identify emerging opportunities in the biotechnology and specialty pharmaceutical space ahead of major catalysts like earnings reports, Tickeron's AI Screener offers a powerful discovery tool. The AI Screener is an AI-powered stock and ETF screening platform that enables traders and investors to filter thousands of securities using customizable criteria including technical patterns, fundamental metrics, volatility profiles, and proprietary AI-driven signals. Users can narrow their search by industry, market capitalization, performance indicators, and chart patterns to surface trade ideas, breakout candidates, and trending names far more efficiently than through manual screening. Exploring the AI Screener can help market participants stay ahead of key earnings events and sector rotations.

Market Reaction and Investor Sentiment

Heading into the Q2 2026 report, sentiment around UroGen Pharma stock appears broadly constructive. Shares closed near the $40.40 mark on July 29, 2026, not far from their 52-week high of $43.93 and well above the 52-week low of $15.86. The stock has rallied more than 125% over the past year, reflecting growing confidence in the ZUSDURI launch story. Analyst consensus rates URGN a Strong Buy with an average price target of approximately $44.75, according to StockAnalysis. However, historical earnings-day reactions have been volatile: Q4 2025 results (reported March 2026) triggered a 12.4% intraday decline despite an EPS beat, as revenue missed consensus. Q3 2025 results (November 2025) produced a 21.9% surge. This pattern of outsized post-earnings moves underscores the binary risk embedded in this event, particularly given elevated expectations around ZUSDURI's commercial trajectory.

Forward Outlook and Key Factors to Monitor

Beyond the Q2 top- and bottom-line figures, several forward-looking themes will shape UroGen Pharma's narrative through the remainder of 2026 and into 2027.

First among these is ZUSDURI's prescriber base expansion. Management disclosed 256 unique prescribers and 103 repeat prescribers at the end of Q1 2026, representing substantial growth from 102 and 32, respectively, at year-end 2025. Yet this still represents only a fraction of the addressable urology market. The pace at which new prescribers are added in Q2 — and, critically, how many convert into repeat prescribers — will be the clearest signal of long-term demand durability. The company estimates a $5 billion total addressable market for ZUSDURI with potential peak annual revenues exceeding $1 billion.

Second, pipeline catalysts are approaching. UGN-103, the company's next-generation mitomycin formulation, reported a 77.8% complete response rate at three months in the Phase III UTOPIA trial. A New Drug Application (NDA) is planned for the second half of 2026, with six-month durability data expected midyear. Additionally, UGN-104 Phase III enrollment is expected to complete by year-end 2026, and UGN-501 is set to enter Phase I trials in non-muscle invasive bladder cancer (NMIBC). Any updates on these timelines during the earnings call could move the stock independently of commercial metrics.

Finally, financial sustainability remains a central question. With $140.3 million in cash as of March 31, 2026, and full-year operating expense guidance of $240 million to $250 million, the company is not yet self-funding. The rate of cash consumption relative to ZUSDURI revenue growth will determine whether additional financing is needed before reaching breakeven — a threshold analysts currently project for 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations